EMA on Track to meet Targets

The European Medicines Agency's Management Board discussed the Agency's annual mid-year report for 2012 at its meeting on 4 October. The mid-year report from the Executive Director to the Management Board provides an overview of the Agency's progress from January to June in implementing its 2012 work programme.

Presenting the report to the Board, Executive Director Guido Rasi said that the progress of the Agency's activities so far in 2012 was encouraging. "Our main performance indicators have been met. The mid-year report indicates that the Agency is on target to meet its core business objectives for 2012," he said.

Report highlights:

• The number of new marketing-authorisation applications for new human medicines received so far is largely in line with 2011 figures for the same period.
• Requests for scientific advice and protocol assistance for new human medicines had increased by almost 14% and 24%.
• Significant increase in the number of applications for orphan designation (30% above the same period in 2011).
• Applications for new veterinary medicines remain at around the same level as 2011.
• Pharmacovigilance legislation - implementation progresses as planned

Source: EMA press release